Skip to main content

Table 1 Summary characteristics of included studies

From: One- and two-stage surgical revision of infected elbow prostheses following total joint replacement: a systematic review

  One-stage revision Two-stage revision
Eligible studies
 Total number of studies included 2 7
Participants
 Total number of participants 7 87
 Total number of re-infections 1 11
 Median (IQR) age (years) 64.9 (62.7–67.0) 64.7 (59.7–65.0)
 Median (IQR) males (%) 0.0 (0.0–0.0) 31.0 (29.5–35.8)
Location
 Europe 2 (7) 4 (59)
 North America 3 (28)
 Asia
Study and surgery characteristics
 Median (IQR) time from index surgery to infection diagnosis (months) 40.5 (40.5–40.5) 38.0 (24.0–51.9)
 Median (IQR) duration of infection symptoms (days) 60.4 (60.4–60.4)
 Median (IQR) time from index surgery to revision surgery (months) 57.1 (48.2–66.0)
 Median (IQR) from infection diagnosis to revision surgery (months) 15.0 (15.0–15.0)
 Median (IQR) interval between stages (months) NA 6.1 (4.7–7.7)
 Median (IQR) follow-up (years) 5.4 (4.0–6.8) 4.1 (3.0–4.3)
 Median (IQR) duration of antibiotics (days) 30.5 (11.3–49.7)
 Median (IQR) duration of IV antibiotics (days) 37.2 (37.2–37.2) 8.8 (8.8–8.8)
 Median (IQR) duration of oral antibiotics (days) 2.5 (2.5–2.5)
 Methodological quality (IQR) 10.5 (10.0–11.0) 10.0 (10.0–11.0)
Baseline clinical characteristics
 Median (IQR) Range of motion (°) 72.0 (50.0–94.0)
 Median (IQR) Extension 36.3 (36.3–36.3)
 Median (IQR) Flexion 101.3 (101.3–101.3)
 Median (IQR) MEPS 28.0 (22.9–52.5)
 Median (IQR) Pain score 15.0 (15.0–15.0)
  1. IQR Interquartile range, IV Intravenous, MEPS Mayo elbow performance score, NA Not applicable; values are number of studies (number of participants) unless stated otherwise